Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

NCT05767346 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

175

Enrollment

INDUSTRY

Sponsor class

Conditions

Obstructive Hypertrophic Cardiomyopathy (oHCM)

Interventions

DRUG: Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)
DRUG: Placebo to match aficamten
DRUG: Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg)
DRUG: Placebo to match metoprolol succinate

Sponsor

Cytokinetics

Collaborators

[object Object]